TrialCardiovascular diabetology2024

Impact of baseline FIB-4 score on efpeglenatide benefits on cardiovascular outcomes in people with type 2 diabetes: a participant-level exploratory analysis of the AMPLITUDE-O trial.

Stefano Del Prato et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.